Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin

Coronary heart disease (CHD) is the leading cause of morbidity and mortality in the Western world, with hypercholesterolemia as the major risk factor. The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors represent the most efficient drugsfor the treatment of hypercholesterolemia. They lowe...

Full description

Bibliographic Details
Published in:Journal of clinical pharmacology, Vol. 42, No. 8 (2002), p. 835-45
Main Author: Igel, Michael
Other Involved Persons: Sudhop, Thomas ; von Bergmann, Klaus
Format: Article
Language:English
ISSN:1552-4604
Item Description:Date Completed 21.02.2003
Date Revised 26.08.2019
published: Print
ErratumIn: J Clin Pharmacol. 2003 Sep;43(9):1015
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Subjects:
QR Code: Show QR Code